

# SUBJECT INDEX

## A

- Acetyl-coenzyme A (CoA), 40, 180, 186, 189-91, 332-33 continuous regulation of, 40
- Acetyl-coenzyme A carboxylase (ACC), 332-33
- Acinetobacter calcoaceticus* 69/V, 43-44
- Acrodermatitis, 3, 442
- Actinomycin D, 336
- Acylcarnitine, 179, 188-98 deficiency, 190-98 esters, 56-57
- Acyl-coenzyme A, 179-80, 186, 189-91, 193
- Acyl-coenzyme A:retinol acyltransferase (ARAT), 262, 270-71
- Adenylyl cyclase, 354-56
- Adipose tissue glucose homeostasis and, 209, 219-20 glycerol-3-phosphate acyltransferase expression in, 335
- Adrenocorticotrophic hormone (ACTH), 65
- Aging osteoporosis and, 233-53 vitamin D receptor polymorphisms and, 233, 240, 243-53
- AIDS dietary oxidative stress and pathogenesis of, 93, 108, 111
- A-kinase anchoring proteins (AKAPs), 357
- Angiotensin-converting enzyme, 9
- Antioxidants carotenoids, 20
- Apo-cellular retinol-binding protein (apoCRBP), 267
- Apolipoprotein AI regulatory protein-1 (ARP-1), 306, 312
- Apolipoprotein E, 303, 306
- Apoptosis, 150
- Ascorbic acid glycosides of, 278, 292
- ATF-1, 368-69
- Atherosclerosis cholesterol ester transfer protein and, 297, 318-32

- Atherosclerotic cardiovascular disease potential of inulin for risk reduction of, 117

## B

- Bacillus subtilis*, 42
- Bactericidal/permeability increasing protein (BPI), 298-323
- Benzylamine oxidase, 151
- Bifidogenic bacteria inulin-type fructans and, 124-26
- Bile, 386
- Bile salt-dependent retinyl ester hydrolase (BSDREH), 264-66, 268, 272
- Bile salt-independent retinyl ester hydrolase (BSIREH), 266-79
- Bioavailability zinc, 1, 4-6 calcium-phytate interactions, 6 casein-gelatin-based diets, 4-6 soy protein diets, 5-6
- Body composition of livestock, 63-84 genetic engineering, 63, 78-84 antisense or ribozyme strategies, 81 gene inhibition, 81 inducible gene expression, 80 somatic cell engineering, 83-84 target genes, 82 transgenic livestock, 79-80 growth promotants, 77-78 hormone patterns and, 74 nutritional manipulation, 76-77 postnatal development, 72-76 prenatal development, 65-72 gender and, 72 insulin levels and, 72 protein accretion rate and, 74
- Bone-mineral density (BMD), 235-53 genetic association studies, 239-53 age and, 245 apolipoprotein E phenotype, 242

- body composition and, 245-47 calcium intake and, 247, 249 collagen gene polymorphisms, 242 estrogen receptor gene polymorphisms, 241-42 race and, 245 vitamin D receptor gene polymorphisms, 243-53 vitamin D supplementation and, 249-50
- $\gamma$ -Butyrobetaine carnitine metabolism in microorganisms and, 39, 41-42, 44-47
- Buyrobetaine hydrolase, 181-83

## C

- Calcium-channel function zinc and, 1, 12-15
- Calcium metabolism, 233-53 osteoporosis and, 233-53 intestinal calcium absorption, 250-51 vitamin D receptor polymorphisms and, 233, 240, 243-53
- Calcium-phytate interactions zinc and, 6
- cAMP, 343-44, 353-72 regulation of fatty acid synthase generation and, 343-44 regulation of nutritional metabolism and energy and, 354
- cAMP response element binding protein (CREB), 353-55, 360-72 binding protein (CBP), 262-65
- cAMP response element modulator (CREM), 353, 367-68
- cAMP signaling pathway, 354-72 adenylyl cyclases and, 354-56 phosphatases, 359 PKA and, 353-59 PKA inhibitors, 358-59 transcription factors, 359-72 AP-2, 269 ATF-1, 368-69

- CREB, 360-67  
CRM, 367-68  
NF- $\kappa$ B, 369  
nuclear receptors, 370-71
- Cancer, 344, 413-32  
lipogenic enzyme control and, 344  
see also Prostate cancer
- Carbonic anhydrase, 3
- Carboxysterases  
hydrolysis of retinyl esters and, 259-60, 264-69
- Carnitine  
acyl-, 179, 188-98  
biosynthesis, 53, 180-82  
deficiency, 179, 184-88, 190-98  
nutritional interventions, 197-98  
functions, 40-41  
genetic disorders, 179-98  
homeostasis, 53-57  
kidneys and, 53-57  
insufficiency, 186-87  
metabolism, 39-57  
bacterial degradation, 47  
exercise and, 52-53  
in mammals, 46-56  
in microorganisms, 41-44  
nutrition, 187-88  
transport, 182-88  
defects, 179, 184-88  
defects in, 184-88
- Carnitine palmitoyltransferase (CPT), 179, 189-98
- Carotenes, 19-33  
 $\alpha$ -, 20, 25-26  
bioavailability, 25  
 $\beta$ -, 20-33  
bioavailability, 25-26  
matrix, 27  
sex and age and, 32
- Carotenoids, 19-33, 413, 428-29  
alcohol intake and, 29-30  
bioavailability and  
bioconversion, 20-33  
matrix and, 27-28  
methods for determining, 21-22  
SLAMGENHI, 22-33  
bioconversion to retinol, 19-33  
dietary fat and, 29  
dietary fiber and, 29  
prostate cancer risk and, 413, 428-29
- Casein-gelatin-based diets, 4-6  
zinc and, 4-6
- Cellular retinol-binding protein, 272
- Chicory, 117
- Cholesterolemia  
inulin-type fructans and, 131-32
- Cholesteryl ester transfer protein (CETP)  
atherosclerosis and, 297, 318-23  
gene expression, 301-9  
diet and, 302-9  
endogenous  
hypercholesterolemia and, 302-9  
insulin resistance and, 309-10  
mechanism of neutral lipid transfer, 300-1  
structure, 298-300  
transgenic mice studies, 303-8, 310-12, 318-19
- Collagen  
lysyl topa quinone and, 154
- Colon, 117
- Colostrum, 73
- Constipation  
potential of inulin for risk reduction, 117
- Copper, 15-16, 153, 441, 451-56  
deficiency, 153  
ion transport, 441, 451-56
- Copper-containing amine  
oxidases, 145-67  
cysteinyl-tyrosine (CT), 145, 148-50, 153  
lysyl topa quinone (LTQ), 145-50, 154-55, 161-67  
pyrroloquinoline quinone (PQQ), 145-50, 155-67  
topa quinone, 145-54, 161-67  
diamine oxidase (DAO), 150-54, 162-64, 166  
monamine oxidases (MAO), 150-54, 164, 166  
plasma amine oxidase (PAO), 150-54, 164, 166  
semicarbazide-sensitive amine oxidase (SSAO), 150-54, 164, 166-67  
see also Redox cofactors
- Corticotropin-releasing factor (CRF), 65
- Corynebacterium glutamicum*, 42
- Coxsackievirus pathogenesis  
dietary oxidative stress and, 93, 95-100, 108, 110-12  
iron toxicosis and, 99  
selenium deficiency and, 93, 95-97, 100
- vitamin E deficiency and, 93, 98
- CREB, see cAMP response element binding protein
- CREB-binding protein (CBP), 362-65
- Crotonobetaine  
carnitine metabolism in microorganisms and, 39, 44-47
- Cyclic adenosine monophosphate, see cAMP
- Cyclic AMP, see cAMP
- Cyclohexamide, 336
- Cysteinyl-tyrosine (CT), 145, 148-50, 153
- ## D
- Diabetes mellitus, non-insulin dependent (NIDDM, type 2)  
inulin and potential for risk reduction, 117  
lipogenic enzyme control and, 344  
transgenic mice studies, 209-27  
adipose tissue, 209, 219-20  
liver, 209, 220-25  
pancreatic  $\beta$ -cells, 207, 209-13  
skeletal muscle, 209, 213-19
- Diamine oxidase (DAO), 150-54, 162-64, 166
- Diarrhea  
potential of inulin for risk reduction, 117
- Dihydrotestosterone, 419
- DNA-binding proteins  
zinc and, 12
- DNA synthesis  
zinc and, 7-8, 12
- ## E
- Ecdysone, 80
- Enteropathica, 442
- Escherichia coli*, 44, 46-47
- N-Ethylmaleimide (NEM), 335
- ## F
- Fanconi syndrome, 187
- Fatty acid biosynthesis, 331-45  
fatty acid synthase and, 334  
mitochondrial  
glycerol-3-phosphate acetyltransferase (GPAT) and, 331, 334

- Fatty acid oxidation  
mitochondrial carnitine system  
and, 189-97  
mitochondrial  
acylcarnitine-carnitine  
translocase and, 192-93
- Fatty acids  
prostate cancer risk and, 413,  
421-24
- Fatty acid synthase (FAS),  
331-45  
transcriptional regulation of  
genes, 331, 334-45  
glucagon and, 336-38,  
343-44  
insulin and, 336-43
- Feed-conversion ratio, 64
- somatotropin/insulin-like  
growth factor and, 64
- Fermentation  
dietary fructans and, 117-38  
in vivo, 124-26  
large bowel, 123, 126-27  
products of digestion, 126  
tecquilla, 119
- Fibroblast growth factor (FGFs),  
66-69
- Fructans, 117-38  
define, 118  
as dietary carbohydrate,  
119-20  
chemistry, 118  
fermentation, 117-38  
health claims and scientific  
evidence, 133-38  
large bowel, 123, 126-27  
glycemia modulation, 129-30  
inulin, 117-38  
plant sources, 118  
triglyceridemia and, 130-32  
types used in food industry,  
119-20  
uremia and, 132  
see also Inulin
- G**
- Gene therapy, 63, 78-84
- Genetic engineering  
livestock body composition and,  
63, 78-84  
antisense or ribozyme  
strategies, 81  
gene inhibition, 81  
inducible gene expression, 80  
somatic cell engineering,  
83-84  
target genes, 82  
transgenic livestock,  
79-80
- Germline transgenesis, 63,  
78-84
- Glucagon, 331, 336-38,  
343-44  
regulation of fatty acid  
synthase gene and,  
343-44
- Glucocorticoids, 65, 331
- Gluconeogenesis  
cAMP and, 354  
phosphoenolpyruvate  
carboxykinase (PEPCK)  
and, 354
- Glucose, 162-63, 207-27,  
331-34, 336-44  
fatty acid synthase transcription  
and, 336-44  
glycerol-3-phosphate  
acyltransferase (GPAT)  
transcription and, 336-43  
hexosamine biosynthesis and,  
217-18  
homeostasis, 207-27  
insulin-mediated signal  
transduction and, 218-19  
ion channel conductance, 213  
metabolism  
transgenic mice studies,  
207-27  
monoxide glucose disposal,  
217  
oxidase, 162-63  
phosphorylation, 211-13,  
216-17  
transport, 211, 214-16
- Glucosides, 277-93  
ascorbic acid, 278, 292  
niacin, 277, 289, 293  
pantothenate, 277, 291-92  
pyridoxine, 277  
retinol, 277, 291  
riboflavin, 277, 288-89  
vitamin B<sub>6</sub>, 278-88, 293  
vitamin D, 277-78, 290-91
- Glycemia  
fructans and modulation of,  
129-30
- Glycerol-3-phosphate  
acyltransferase (GPAT),  
331-45  
isoforms of, 335  
transcriptional regulation of  
genes, 331, 334-45  
glucagon and, 336-38  
insulin and, 336  
nutritional and hormonal,  
335-38
- Glycogen  
role of cAMP and PKA in  
breakdown of, 354
- Gold thioglucose, 99-100
- Growth differentiation factor-8  
(GDF-8), 69
- Growth hormone releasing factor  
(GRF), 65, 71, 79  
transgenic augmentation of, 79
- H**
- Haemophilus influenzae*, 42
- Hemochromatosis, 442
- Hepatitis pathogenesis  
dietary oxidative stress and,  
93, 98  
iron toxicosis and, 98-99
- High-density lipoprotein (HDL),  
297-301, 311-12, 315-17,  
320-21, 323
- Hip axis length (HAL), 235
- Histaminase, see Diamine oxidase
- Histone acetyltransferase (HAT),  
363
- Hydrolases, 259, 264-73  
bile salt-dependent retinyl ester  
hydrolase, 264-66, 268,  
270, 272  
bile salt-independent retinyl  
ester hydrolase, 266-70,  
272
- Hyperlipidemia  
lipogenic enzyme control and,  
344
- I**
- Inducible cAMP early repressor  
(ICER), 368
- Influenza pathogenesis  
dietary oxidative stress and, 93,  
99-100, 108-12  
gold thioglucose and, 99-100  
host immune system and,  
100-3
- Inulin, 117-38  
calcium absorption, 128  
chicory, 117, 119-21  
as dietary carbohydrate, 120-21  
classification, 121  
sources, 120-21  
fermentation  
in large bowel, 123  
in vitro, 123  
in vivo, 124-26  
health claims and scientific  
evidence, 133-38  
potential in risk reduction of  
disease, 117, 134-38  
triglyceridemia and, 130-32  
types used in food industry,  
119-20  
uremia and, 132

- Insulin, 331, 336-43  
   gene regulation and  
     fatty acid synthase and  
       glycerol-3-phosphate  
       acyltransferase, 336-43  
   type-2 diabetes and, 209-27  
   adipose tissue, 209, 219-20  
   glucose homeostasis and,  
     208-27  
   liver, 207, 209, 220-25  
   pancreatic  $\beta$ -cells, 207,  
     209-13, 226-27  
   skeletal muscle, 207, 209,  
     213-19  
   resistance  
     cholesteryl ester transfer  
       protein and, 309-10  
 Insulin-like growth factors, 65,  
   67-77  
   binding proteins (IGFBPs), 69,  
     75-77  
   body composition and  
     nutritional manipulation, 76  
   patterns of development, 76  
   I, 65-68  
   II, 68  
   transgenic augmentation of, 79  
 Iron  
   ion transport, 441, 443-51  
   overload, 98-99  
     chronic hepatitis and, 98-99  
     vitamin E as antidote, 98

## K

- Keshan disease, 95, 108-9  
 Kidneys  
   carnitine homeostasis and,  
     53-57  
 Kinase inducible domain (KID),  
   361  
 Knockout mice  
   macrophage inflammatory  
     protein 1 $\alpha$ , 104  
   glutathione peroxidase 1,  
     105-7

## L

- Lecithin, 28  
 Lecithin:retinol acyltransferase  
   (LRAT), 262, 271-72  
 Lecithyl cholesterol  
   acyltransferase (LCAT), 301,  
   319  
 Levan, 118  
 Lipases  
   hydrolysis of retinyl esters and,  
     259-60, 264, 269-71

- Lipogenesis, 331-45  
 Lipopolysaccharide binding protein  
   (LBP), 298-99, 301  
 Liver  
   chromatin structure of, 341  
   enzymes catalyzing hydrolysis  
     of retinyl esters, 259-73  
   glucose homeostasis and,  
     220-25  
   alterations in insulin action,  
     223, 225  
   hepatic glucose uptake and  
     output, 220-23  
   glycerol-3-phosphate  
     acyltransferase expression  
       in, 335  
 Livestock, see Body composition  
   of livestock  
 Low-density lipoproteins (LDL),  
   303, 311, 316-17, 322  
 Lycopene, 26, 28, 428-29  
   Olestra and reduced plasma  
     concentrations of, 429  
   prostate cancer risk reduction  
     and, 428-29  
 Lysine  
   carnitine biosynthesis and, 53  
 Lysyl oxidate (LO), 155, 159, 166  
 Lysyl topa quinone (LTQ),  
   145-50, 154-55, 161-67  
   medical and other uses, 161-67

## M

- Manganese ion transport, 441,  
   457-60  
 Melanogenesis, 161  
 Menkes disease (syndrome),  
   153-55, 442  
 Metal ion transport, 441-63  
   copper, 441, 451-56  
   iron, 441, 443-51  
   manganese, 441, 457-60  
   zinc, 441, 460-63  
 Metalloenzymes  
   zinc and, 11-12  
 Metallothionein gene  
   zinc and, 80  
 Methionine  
   carnitine biosynthesis and, 53  
 Methylamine dehydrogenase  
   (MADH), 149  
 Mitochondrial carnitine system,  
   189-97  
   fatty acid oxidation and,  
     189-97  
   mitochondrial  
     acylcarnitine-carnitine  
       translocase, 192-93  
   deficiency, 193

- Monoamine oxidases (MAO),  
   150-54, 164, 166  
 Mouse mammary tumor virus  
   (MMTV) promoters, 370  
 Mucins, 386  
 Muscle development  
   maternal influences, 70-72  
   proliferation and differentiation,  
     66-70  
   somatotropin/insulin-like  
     growth factor axis and,  
       63-64  
   stages, 65  
 Myocyte-specific  
   enhancer-binding factor 2  
   (MEF2), 66  
 Myogenesis, 65-72  
   see also Muscle development  
 Myogenesis determination factor  
   (Myod), 66-70  
 Myoglobinuria  
   exercise-induced, 195  
 Myostatin, 83

## N

- NADPH, 332  
 Nerve function  
   zinc and, 1, 10-11  
 Niacin  
   glycosides of, 277, 289, 293  
 Nitrogen cycling, 385-406  
   amino acids, 395-406  
   bile, 386  
   cell debris, 386  
   digesta, 387-95  
   gastrointestinal tissue and,  
     402-6  
   glutathione and, 380  
   mucins, 386  
   protein synthesis and,  
     386-406  
   secretions into gut, 386-87  
   urea, 386, 393-95  
 Nuclear factors, 353

## O

- Obesity  
   diabetes type-2 and, 209  
   lipogenic enzyme control and,  
     344  
 Olestra  
   reduction of plasma  
     concentrations of lycopene  
       and, 429  
 Oligofructose, 117  
 Omega-3 fatty acids, 97-98  
 Osteoporosis, 233-53

- age and, 245  
 apolipoprotein E phenotype, 242  
 body composition and, 245-47  
 collagen gene polymorphisms, 242  
 diet and, 236  
 genetic association studies, 239-44  
   bone mineral density and, 239-44  
 hip axis length and, 235  
 low bone mineral density and, 235  
 peak bone mass and, 235  
 race and, 236-37  
 vitamin D  
   receptor gene polymorphisms, 243-53  
   supplementation, 249-50  
 Oxidation-reduction (redox)  
   cofactors, 145-67  
   see also Copper-containing amine oxidases  
 Oxidative stress  
   defined, 94  
   dietary, 93-112  
   gold thioglucose and, 99-100  
   host immune system and, 100-3  
   iron overload, 98-99  
   selenium deficiency, 93-97, 199  
   viral infection and, 94-100  
   vitamin E deficiency, 93, 97-98
- P**
- Pancreatic  $\beta$ -cells, 207-13, 226-27  
 diabetes type-2 and, 207, 209-13, 226-27  
 glucose homeostasis and, 208-13  
   glucose phosphorylation, 211  
   glucose transport, 211  
   ion channel conductance, 213  
 Patogenesis  
   glycosides of, 277, 291-92  
 Peak bone mass, 235, 245  
 PEPCK, see Phosphoenolpyruvate carboxykinase  
 Peroxisome proliferator-activated receptor (PPAR), 337  
 Phosphatases, 359  
 Phosphatidylinositol 3-kinase, 68, 343  
 Phosphodiesterases, 350  
 Phosphoenolpyruvate carboxykinase (PEPCK), 334, 337, 342-43, 354  
   cAMP stimulation of gene for, 354  
   gene repression by insulin, 342-43  
 Phospholipid transfer protein (PLTP), 297-323  
   gene expression  
     diet and, 302-9  
     endogenous hypercholesterolemia and, 302-9  
     reverse cholesterol transport and, 315-17  
 Picornavirus family, 94  
 Plasma amine oxidase (PAO), 150-54, 164, 166  
 Plasma lipid transfer proteins, 297-323  
   atherosclerosis and, 318-23  
   cholesterol ester transfer protein (CETP), 297-323  
   phospholipid transfer protein (PLTP), 286-323  
   reverse cholesterol transport and, 315-17, 321  
 Plasma membrane function  
   zinc and, 1, 12-15  
 Polyunsaturated fatty acids (PUFA), 337-38  
 Prebiotics  
   inulin-type fructans, 124-26, 135  
 Probiotics  
   inulin-type fructans, 123  
 Probiol, 308  
 Prostate cancer  
   age and, 416  
   demographics, 418  
   diet and nutrition and, 413-32  
   endocrine factors, 419  
   family history, 417  
   histopathology, 415-16  
   incidence, 417-18  
   nutritional risk factors, 421-32  
     alcohol, 424  
     fatty acids, 421-24  
     lycopene, 428-29  
     protein, 421  
     selenium, 429-30  
     vitamin A, 426-28  
     vitamin D, 430-31  
   sexual and reproductive factors, 419  
 Protein kinase A (PKA), 353-73  
   inhibitors, 358-59  
   phosphorylation and activation of transcription factors by, 353-73  
   regulation of nutrient metabolism and, 354  
   subunits, 356-58  
*Pseudomonas*, 42  
 Pyridosine  
   glycosides of, 277, 279-88, 293  
   enzymatic hydrolysis, 284-86  
   intestinal absorption, 283-84  
   vitamin B<sub>6</sub>, 278-88, 293  
 Pyrroloquinoline quinone (PQQ), 145-50, 155-67  
   as essential nutrient, 157-61  
   medical and other uses, 161-67  
 Pyruvate, 332  
 L-Pyruvate kinase, 334
- Q**
- Quinoproteins, 145-67  
 as essential nutrients, 157-61  
 medical and other uses, 161-67
- R**
- Reactive oxygen species  
 influenza pathogenesis and, 101  
 Redox cofactors, 145-67  
   see also Copper-containing amine oxidases  
 11-*cis* Retinaldehyde, 260  
 Retinoids, 259, 262  
 Retinol, 19-33, 259-73  
   bioconversion from carotenoids, 19-33  
     alcohol intake and, 29-30  
     dietary fat and, 29  
     dietary fiber and, 29  
     SLAMENGI, 22-23  
     zinc and, 31  
   glycosides of, 277, 291  
   metabolism, 259-73  
 Retinyl ester hydrolases (REH)  
   bile salt-dependent, 264-66, 268, 272  
   bile salt-independent, 266-70, 272  
 Retinyl esters, 259-73, 300  
   digestion of, 261  
   cholesterol ester transfer protein and, 300

vitamin A metabolism and, 260-62  
Reverse cholesterol transfer protein  
cholesterol ester transfer protein  
and, 297, 315-17, 321  
Rhodopsin, 260  
Riboflavin  
glycosides of, 277, 288-89  
RNA enterovirus, 94  
RU486, 80

## S

*Saccharomyces cerevisiae*  
metal ion transport in, 441-63  
*Salmonella typhimurium*, 44  
Scavenger receptor BI, 297, 304, 308  
Selenium  
prostate cancer risk and, 429-30  
Selenium deficiency  
oxidative stress and, 93-97, 100, 108-10  
coxsackievirus B3 infection  
and, 93, 95-97, 100  
Keshan disease and, 95, 108-9  
Semicarbazine-sensitive amine  
oxidase (SSAO), 150  
Sex hormone binding globulin  
(SHBG), 419-20  
Signal transduction  
insulin-mediated, 218-19  
zinc and, 1, 12-15  
Signal transduction activating  
transcriptions (STATs), 363  
Skeletal muscle  
glucose homeostasis and, 207, 209, 213-19  
glucose phosphorylation,  
216-17  
glucose transport, 214-16  
hexosamine biosynthetic  
pathway, 217-18  
insulin-mediated signal  
transduction, 218-19  
monoxidative glucose  
disposal, 217  
Sodium dodecyl-sulfate-  
polyacrylamide gel  
electrophoresis, 268  
Somatotropin (ST), 63-64, 71-72, 76-79  
IGF-I and, 77-79  
transgenic augmentation of,  
79  
livestock body composition and  
nutritional manipulation of,  
76-78

Somatotropin/insulin-like growth  
factor axis, 64, 74-79  
body composition and  
nutritional manipulation of,  
74-78  
patterns of development,  
74-76  
Somatostatin, 65, 72  
Soy protein diets  
zinc bioavailability in, 5-6  
Spermatogenesis, 353  
Sterol response element-binding  
proteins, 341

## T

Thyroid hormone, 331  
Thyroid-stimulating hormone,  
358  
Topa quinone (TPQ), 145-50,  
161-67  
uses, 161-67  
Trace element research, 1-16  
zinc and, 1  
Transforming growth factor- $\beta$ , 66,  
67, 69  
Transgenic livestock, 79-84  
Transgenic mice, 81-82, 303-8,  
310-12, 318-19, 209-27  
bovine  $\alpha$ -lactalbumin expression  
and, 81  
cholesterol ester transfer protein  
gene expression and,  
303-8, 310-12, 318-19  
glucose metabolism studies,  
209-27  
adipose tissue, 209, 219-20  
liver, 207, 209, 220-25  
pancreatic  $\beta$ -cells, 207,  
209-13, 226-27  
skeletal muscle, 207, 209,  
213-19  
Translocase, 179  
Transurethral resection of the  
prostate (TURP), 418  
Triacylglycerol biosynthesis,  
331-45  
mitochondrial glycerol-3-  
phosphate acyltransferase  
(GPAT) and, 331,  
334-45  
Triglyceridemia  
inulin-type fructans and, 130  
Trimethylamine  
carnitine metabolism in  
microorganisms and,  
39-44  
6-N-Trimethyllysine, 181-82  
Tryptophan tryptophylquinone  
(TTQ), 145-59, 161-67

medical and other uses,  
161-67  
Tumor necrosis factor (TNF),  
65

## U

Urea, 386, 393-95  
Uremia, 132

## V

Vascular cell adhesion molecule-1  
(V-CAM-1), 369  
Very low-density lipoprotein  
(VLDL), 311-12, 318  
Viral infection pathogenesis  
dietary oxidative stress and,  
93-112  
gold thioglucose and, 99-100  
host immune system and,  
100-3  
iron toxicosis and, 98-99  
knockout mice, 103-7  
selenium deficiency and,  
93-97, 100  
vitamin E deficiency and,  
97-98  
Viral mutation, 93  
Vitamin A  
carotinoids and, 19-33  
hydrolysis of retinyl esters and,  
260-73  
metabolism and transport,  
260-62  
prostate cancer risk and, 413,  
426-28  
Vitamin B<sub>6</sub>  
glycosides of, 278-88, 293  
Vitamin D  
glycosides of, 277-78, 290-91  
osteoporosis and, 233, 236  
prostate cancer risk and, 413,  
430-31  
Vitamin D receptor  
polymorphisms  
osteoporosis and bone-mineral  
density, 233, 240, 243-53  
age and, 245  
body composition and,  
245-47  
calcium intake and, 247, 249  
race and, 245  
vitamin D supplementation  
and, 249-50  
as predictor of disease, 252  
Vitamin E, 93, 97-98, 110, 156  
deficiency, 93, 97-98, 110  
iron overload and, 98  
oxidative stress and, 93, 98

Vitamin K, 236

## W

Wilson disease, 442

## Z

Zinc

angiotensin-converting enzyme  
and, 9

bioavailability in food, 4-6  
calcium-channel functions,  
12-15  
calcium-phytate interactions,  
6  
 $\beta$ -carotene utilization and,  
31  
dietary fatty acids and, 8  
DNA synthesis and, 7-8, 12  
erythrocyte stability and,  
10, 12  
IGF-I and, 8

ion transport, 441, 460-63  
locomotion and, 10-11  
metalloenzymes and,  
11-12  
peripheral nerves and,  
10-11  
plasma membrane function and,  
1, 12-15  
retinol-binding protein  
synthesis and, 31  
signal transduction and, 1, 8-9,  
12-15





